Compare SNEX & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SNEX | APGE |
|---|---|---|
| Founded | 1924 | 2022 |
| Country | United States | United States |
| Employees | 5400 | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 4.7B |
| IPO Year | 1996 | 2023 |
| Metric | SNEX | APGE |
|---|---|---|
| Price | $77.76 | $79.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 13 |
| Target Price | $81.33 | ★ $109.25 |
| AVG Volume (30 Days) | 512.3K | ★ 1.0M |
| Earning Date | 05-06-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.50 | N/A |
| Revenue | ★ $132,378,200,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.69 | N/A |
| P/E Ratio | $31.11 | ★ N/A |
| Revenue Growth | ★ 32.53 | N/A |
| 52 Week Low | $65.58 | $26.20 |
| 52 Week High | $132.57 | $85.04 |
| Indicator | SNEX | APGE |
|---|---|---|
| Relative Strength Index (RSI) | 27.64 | 60.14 |
| Support Level | N/A | $73.06 |
| Resistance Level | $97.49 | $81.04 |
| Average True Range (ATR) | 3.83 | 4.62 |
| MACD | -3.43 | 0.96 |
| Stochastic Oscillator | 21.15 | 73.26 |
StoneX Group Inc is a Global brokerage and financial services firm. Its service offerings are execution, OTC / Market-Making, advisory services, Global payment solutions, market intelligence, Physical Trading and clearing services. The firm operates in four segments: Commercial, Institutional, Self-Directed/Retail, and Payments. Its customers include governmental and nongovernmental organizations, commercial banks, brokers, institutional investors, and investment banks. The company operates in the United States, South America, Europe, the Middle East and Asia, and other countries, out of which the majority of revenue is generated from the Middle East and Asia Region.
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.